Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus radiotherapy and S-1 versus radiotherapy and S-1 in older patients with esophageal squamous cell carcinoma
ChiCTR2500096027Phase 2Recruiting
- Sponsor
- Huai'an First People's Hospital
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sintilimab and tegafur in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Huai'an First People's Hospital. Primary endpoints: Progression-free survival and Safety. Started Jan 2025; status: recruiting.
02
Drugs
sintilimabtegafur
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2500096027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500096027.